東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Oncology." ]

切換: 標籤 | MARC模式 | ISBD

Circulating tumor DNA as a candidate...

Anand, Sanya.

FindBook

Google Book

Amazon

博客來

Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis./
作者:	Anand, Sanya.
面頁冊數:	60 p.
附註:	Source: Masters Abstracts International, Volume: 55-03.
Contained By:	Masters Abstracts International55-03(E).
標題:	Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1605980
ISBN:	9781339354415

Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis.
Anand, Sanya.

Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis. - 60 p.

Source: Masters Abstracts International, Volume: 55-03.

Thesis (M.S.)--Icahn School of Medicine at Mount Sinai, 2016.

While CA-125 is an FDA-approved biomarker used for monitoring ovarian cancer, levels can rise non-specifically in patients with non-cancerous conditions and stay within a normal range in the presence of persistent disease, making CA-125 inadequate for screening and surveillance. We have developed an efficient pipeline that identifies cancer-specific mutations in each patient's tumor and monitors circulating tumor DNA (ctDNA) levels using droplet digital PCR. Using this platform, we tested and detected ctDNA in 11/12 patients with ovarian cancer. Undetectable levels of ctDNA post-treatment were associated with improved overall survival (p = 0.0179). In six patients, ctDNA levels were detectable prior to CA-125 levels rising above the threshold level of 35 U/ml, indicating that ctDNA has the potential to be a more sensitive and broadly applicable tumor marker for ovarian cancer than CA-125.

ISBN: 9781339354415Subjects--Topical Terms:

530508
Genetics.

Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis.
LDR:01780nmm a2200277 4500 001 2072554
005 20160808080955.5
008 170521s2016 ||||||||||||||||| ||eng d
020 $a 9781339354415
035 $a (MiAaPQ)AAI1605980
035 $a AAI1605980
040 $a MiAaPQ $c MiAaPQ
100 1 $a Anand, Sanya. $3 3187749
245 1 0 $a Circulating tumor DNA as a candidate biomarker for ovarian cancer surveillance and prognosis.
300 $a 60 p.
500 $a Source: Masters Abstracts International, Volume: 55-03.
500 $a Adviser: John Martignetti.
502 $a Thesis (M.S.)--Icahn School of Medicine at Mount Sinai, 2016.
520 $a While CA-125 is an FDA-approved biomarker used for monitoring ovarian cancer, levels can rise non-specifically in patients with non-cancerous conditions and stay within a normal range in the presence of persistent disease, making CA-125 inadequate for screening and surveillance. We have developed an efficient pipeline that identifies cancer-specific mutations in each patient's tumor and monitors circulating tumor DNA (ctDNA) levels using droplet digital PCR. Using this platform, we tested and detected ctDNA in 11/12 patients with ovarian cancer. Undetectable levels of ctDNA post-treatment were associated with improved overall survival (p = 0.0179). In six patients, ctDNA levels were detectable prior to CA-125 levels rising above the threshold level of 35 U/ml, indicating that ctDNA has the potential to be a more sensitive and broadly applicable tumor marker for ovarian cancer than CA-125.
590 $a School code: 1734.
650 4 $a Genetics. $3 530508
650 4 $a Oncology. $3 751006
690 $a 0369
690 $a 0992
710 2 $a Icahn School of Medicine at Mount Sinai. $b Genetics and Genomic Sciences. $3 3187750
773 0 $t Masters Abstracts International $g 55-03(E).
790 $a 1734
791 $a M.S.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1605980